Cigna (NYSE:CI) Releases FY21…

Cigna (NYSE:CI) issued an update on its FY21 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $20.35 for the period, compared to the Thomson Reuters consensus estimate of $20.41.

Cigna stock traded up $0.40 during midday trading on Monday, reaching $226.29. The stock had a trading volume of 14,192 shares, compared to its average volume of 1,906,749. Cigna has a 12 month low of $190.88 and a 12 month high of $272.81. The company has a market capitalization of $75.00 billion, a P/E ratio of 9.49, a PEG ratio of 0.97 and a beta of 0.87. The company has a fifty day moving average price of $213.12 and a two-hundred day moving average price of $217.01. The company has a current ratio of 0.49, a quick ratio of 0.49 and a debt-to-equity ratio of 0.67.

Cigna (NYSE:CI) last released its quarterly earnings results on Thursday, November 4th. The health services provider reported $5.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.23 by $0.50. The business had revenue of $44.30 billion during the quarter, compared to the consensus estimate of $42.88 billion. Cigna had a return on equity of 13.72% and a net margin of 4.93%. The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.41 EPS. On average, equities research analysts predict that Cigna will post 20.41 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 22nd. Stockholders of record on Tuesday, December 7th were paid a $1.00 dividend. The ex-dividend date was Monday, December 6th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 1.77%. Cigna’s payout ratio is presently 16.81%.


The White House is scared of our country’s lithium supply running out. That’s why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who’s gobbling up land in the lithium-rich Nevada desert.

CI has been the topic of a number of research analyst reports. SVB Leerink restated a hold rating and issued a $223.00 target price on shares of Cigna in a research note on Friday, November 5th. UBS Group lowered their price target on shares of Cigna from $285.00 to $244.00 and set a buy rating on the stock in a report on Monday, October 11th. Jefferies Financial Group lifted their price target on shares of Cigna from $270.00 to $277.00 and gave the stock a buy rating in a report on Friday, November 5th. Morgan Stanley cut shares of Cigna from an overweight rating to an equal weight rating and lowered their price target for the stock from $255.00 to $238.00 in a report on Thursday, December 16th. Finally, The Goldman Sachs Group assumed coverage on shares of Cigna in a report on Tuesday, December 14th. They issued a neutral rating and a $233.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to, Cigna currently has a consensus rating of Buy and a consensus price target of $262.04.

About Cigna

Cigna Corp. engages in the provision of global health services. It operates through the following segments: Evernorth, U.S. Medical, International Markets, and Group Disability and Other. The Evernorth segment includes a broad range of coordinated and point solution health services, including pharmacy solutions, benefits management solutions, care solutions and intelligence solutions.

Read More: Federal Reserve

Earnings History and Estimates for Cigna (NYSE:CI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Cigna right now?

Before you consider Cigna, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Cigna wasn’t on the list.

While Cigna currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Hippo Sighting Report

Help us out, we really appreciate it.

Help contribute to our research, and let us know if you have seen similar situations that we may have missed. Our team will review the details you provide and add to our main list once we verify the information.

stay informed

Subscribe and get the updated Hippo List.

Get notified when we release our updated lists by email.

Make a Donation

Thank you for subscribing!

We will send you an email to confirm your details.  Welcome aboard!

Thanks for sending us your report.

We will review your information, and publish in on our list once we validate the details.